China SXT Pharmaceuticals Key Executives
This section highlights China SXT Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at China SXT Pharmaceuticals
(Showing 0 of )
China SXT Pharmaceuticals Earnings
This section highlights China SXT Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
Time:
Est. EPS:
$-
Status:
Unconfirmed
Last Earnings Results
Date:
October 30, 2023
EPS:
$-
Est. EPS:
$-
Revenue:
$-
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.
Healthcare
Drug Manufacturers - Specialty & Generic
$2.16
Stock Price
$29.73M
Market Cap
75
Employees
Taizhou, None
Location
Financial Statements
Access annual & quarterly financial statements for China SXT Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.93M | $1.97M | $2.60M | $4.78M | $5.16M |
| Cost of Revenue | $1.37M | $1.55M | $1.35M | $1.94M | $2.46M |
| Gross Profit | $553.97K | $426.27K | $1.25M | $2.84M | $2.70M |
| Gross Profit Ratio | 28.73% | 21.62% | 48.10% | 59.43% | 52.37% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $2.64M | $5.65M | $5.52M | $3.45M | $2.46M |
| Selling and Marketing Expenses | $433.57K | $387.45K | $924.54K | $1.59M | $1.58M |
| Selling General and Administrative Expenses | $3.07M | $6.03M | $6.44M | $5.04M | $4.04M |
| Other Expenses | $- | $149.51K | $-181.58K | $871.65K | $-73.77K |
| Operating Expenses | $3.07M | $6.03M | $6.44M | $5.04M | $4.04M |
| Cost and Expenses | $4.44M | $7.58M | $7.79M | $6.97M | $6.50M |
| Interest Income | $- | $476.78K | $36.70K | $1.11M | $3.35M |
| Interest Expense | $544.28K | $476.78K | $218.28K | $1.62M | $3.35M |
| Depreciation and Amortization | $203.25K | $250.16K | $320.01K | $345.41K | $331.84K |
| EBITDA | $-2.35M | $-5.21M | $-5.05M | $-1.85M | $-1.01M |
| EBITDA Ratio | -121.91% | -264.13% | -194.11% | -38.76% | -19.55% |
| Operating Income | $-2.52M | $-5.61M | $-5.19M | $-2.20M | $4.28M |
| Operating Income Ratio | -130.42% | -284.40% | -199.43% | -45.99% | 83.00% |
| Total Other Income Expenses Net | $-583.32K | $-327.26K | $-218.28K | $-743.79K | $-9.05M |
| Income Before Tax | $-3.10M | $-5.93M | $-5.41M | $-2.94M | $-10.39M |
| Income Before Tax Ratio | -160.67% | -301.00% | -207.82% | -61.56% | -201.26% |
| Income Tax Expense | $- | $476.78K | $328.15K | $-192.68K | $-101.72K |
| Net Income | $-3.10M | $-5.93M | $-5.74M | $-2.75M | $-10.29M |
| Net Income Ratio | -160.67% | -301.00% | -220.43% | -57.52% | -199.29% |
| EPS | $-3.57 | $-22.23 | $-137.92 | $-95.48 | $-832.08 |
| EPS Diluted | $-3.57 | $-22.23 | $-137.92 | $-95.48 | $-832.08 |
| Weighted Average Shares Outstanding | 867.42K | 266.97K | 41.59K | 28.78K | 12.36K |
| Weighted Average Shares Outstanding Diluted | 867.42K | 266.97K | 41.59K | 28.78K | 12.36K |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $494.46K | $494.46K | $939.58K | $469.79K | $763.39K | $381.70K | $1.21M | $604.14K | $-11.50M | $787.30K | $1.03M | $513.84K | $-9.33M | $458.54K | $1.93M | $1.93M | $5.16M | $973.56K | $3.22M | $1.61M |
| Cost of Revenue | $361.64K | $361.64K | $753.99K | $325.62K | $426.80K | $213.40K | $1.12M | $559.30K | $4.03M | $323.46K | $703.72K | $351.86K | $3.44M | $449.23K | $519.78K | $519.78K | $2.46M | $541.40K | $1.38M | $687.88K |
| Gross Profit | $132.81K | $132.81K | $185.59K | $144.17K | $336.59K | $168.29K | $89.68K | $44.84K | $-15.53M | $463.84K | $323.96K | $161.98K | $-12.77M | $9.31K | $1.41M | $1.41M | $2.70M | $432.16K | $1.84M | $919.69K |
| Gross Profit Ratio | 26.86% | 26.86% | 19.75% | 30.69% | 44.09% | 44.09% | 7.42% | 7.42% | 135.02% | 58.92% | 31.52% | 31.52% | 136.89% | 2.03% | 73.07% | 73.07% | 52.37% | 44.39% | 57.21% | 57.21% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $3.62M | $3.62M | $4.73M | $4.73M | $2.16M | $2.16M | $483.98K | $483.98K | $2.20M | $1.35M | $1.41M | $1.41M | $4.27M | $1.25M | $828.56K | $476.28K | $4.04M | $587.83K | $642.94K | $642.94K |
| Selling and Marketing Expenses | $128.31K | $128.31K | $88.47K | $88.47K | $57.64K | $57.64K | $136.08K | $136.08K | $-924.54K | $263.86K | $198.41K | $198.41K | $-1.59M | $441.39K | $-308.78K | $352.28K | $5.63M | $404.51K | $387.13K | $387.13K |
| Selling General and Administrative Expenses | $3.50M | $3.50M | $9.53M | $4.82M | $4.79M | $2.22M | $1.24M | $620.07K | $-8.44M | $1.61M | $3.22M | $1.61M | $-11.17M | $1.69M | $519.78K | $828.56K | $9.67M | $992.34K | $2.06M | $1.03M |
| Other Expenses | $-6.78M | $-6.78M | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $-3.28M | $-3.28M | $9.53M | $4.82M | $4.79M | $2.34M | $1.24M | $600.00K | $-8.44M | $1.77M | $3.22M | $1.55M | $-11.17M | $1.96M | $519.78K | $381.29K | $9.67M | $3.86M | $2.06M | $1.01M |
| Cost and Expenses | $-2.92M | $-2.92M | $10.29M | $5.15M | $5.22M | $2.56M | $2.36M | $1.16M | $-4.41M | $2.09M | $3.92M | $1.90M | $-7.73M | $2.40M | $1.04M | $901.07K | $12.13M | $4.40M | $3.44M | $1.70M |
| Interest Income | $- | $- | $- | $168.26K | $46.24K | $46.24K | $192.14K | $192.14K | $- | $18.38K | $34 | $35 | $- | $332.18K | $- | $221.04K | $- | $589.11K | $1.09M | $1.09M |
| Interest Expense | $- | $- | $- | $- | $92.49K | $- | $384.29K | $- | $3.56M | $- | $- | $- | $1.98M | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $50.25K | $50.25K | $102.75K | $51.38K | $140.20K | $70.10K | $109.97K | $54.98K | $134.01K | $67.00K | $186.00K | $93.00K | $162.49K | $81.24K | $182.93K | $91.46K | $198.30K | $99.15K | $133.54K | $66.77K |
| EBITDA | $3.68M | $3.68M | $-4.62M | $-4.62M | $-1.98M | $-1.98M | $-520.24K | $-520.24K | $-1.08M | $-1.08M | $-1.35M | $-1.35M | $-1.60M | $-1.60M | $658.23K | $673.37K | $-461.03K | $-461.03K | $-87.21K | $-43.61K |
| EBITDA Ratio | 743.97% | 743.97% | -492.04% | -984.08% | -259.86% | -519.72% | -43.06% | -86.11% | 9.41% | -137.44% | -131.63% | -263.27% | 17.15% | -348.76% | 34.10% | 34.88% | -8.93% | -47.36% | -2.71% | -2.71% |
| Operating Income | $3.42M | $3.42M | $-9.35M | $-4.67M | $-4.46M | $-2.05M | $-1.15M | $-575.22K | $1.28M | $-1.15M | $-2.89M | $-1.45M | $2.42M | $-1.68M | $581.90K | $581.90K | $-6.97M | $-560.18K | $-220.75K | $-110.38K |
| Operating Income Ratio | 691.04% | 691.04% | -995.02% | -995.02% | -583.85% | -538.08% | -95.21% | -95.21% | -11.09% | -145.95% | -281.37% | -281.37% | -25.93% | -366.48% | 30.15% | 30.15% | -134.96% | -57.54% | -6.87% | -6.87% |
| Total Other Income Expenses Net | $-118.09K | $-118.09K | $-347.14K | $-173.57K | $2.24M | $-166.24K | $-344.16K | $-172.08K | $-2.60M | $-171.88K | $1.51M | $62.74K | $-4.70M | $-598.13K | $226.23K | $226.23K | $2.95M | $-3.46M | $-2.13M | $-1.07M |
| Income Before Tax | $3.30M | $3.30M | $-9.70M | $-4.85M | $-4.44M | $-2.22M | $-1.49M | $-747.30K | $2.38M | $-1.32M | $-2.77M | $-1.38M | $4.85M | $-2.28M | $808.14K | $808.14K | $-10.39M | $-4.02M | $-2.35M | $-1.18M |
| Income Before Tax Ratio | 667.16% | 667.16% | -1031.96% | -1031.96% | -581.64% | -581.64% | -123.70% | -123.70% | -20.71% | -167.78% | -269.16% | -269.16% | -51.99% | -496.92% | 41.87% | 41.87% | -201.26% | -412.73% | -73.19% | -73.19% |
| Income Tax Expense | $- | $211.46K | $- | $- | $3 | $- | $4 | $- | $-596.16K | $1.18K | $325.78K | $162.89K | $-75.33K | $213.85K | $117.51K | $117.51K | $-101.72K | $48.28K | $-5.17K | $2.58K |
| Net Income | $3.30M | $3.30M | $-9.70M | $-4.85M | $-4.44M | $-2.22M | $-1.49M | $-747.30K | $2.32M | $-1.32M | $-3.09M | $-1.55M | $5.31M | $-2.06M | $690.63K | $690.63K | $-10.29M | $-3.97M | $-2.35M | $-1.17M |
| Net Income Ratio | 667.16% | 667.16% | -1031.96% | -1031.96% | -581.64% | -581.64% | -123.70% | -123.70% | -20.19% | -167.93% | -300.86% | -300.86% | -56.93% | -450.29% | 35.78% | 35.78% | -199.29% | -407.77% | -73.03% | -73.03% |
| EPS | $2.67 | $2.67 | $-9.67 | $-9.67 | $-5.14 | $-5.14 | $-7.30 | $-7.30 | $-25.39 | $-25.39 | $-49.71 | $-49.71 | $-71.73 | $-71.73 | $24.00 | $24.00 | $-297.04 | $-297.04 | $-103.32 | $-103.32 |
| EPS Diluted | $2.67 | $2.67 | $-9.67 | $-9.67 | $-5.14 | $-5.14 | $-7.30 | $-7.30 | $-25.39 | $-25.39 | $-49.71 | $-49.71 | $-71.73 | $-71.73 | $24.00 | $24.00 | $-297.04 | $-297.04 | $-103.32 | $-103.32 |
| Weighted Average Shares Outstanding | 1.23M | 1.23M | 501.47K | 501.47K | 431.63K | 431.63K | 102.32K | 102.32K | 52.08K | 52.08K | 31.10K | 31.10K | 28.78K | 28.78K | 28.78K | 28.78K | 13.37K | 13.37K | 11.36K | 11.36K |
| Weighted Average Shares Outstanding Diluted | 1.23M | 1.23M | 501.47K | 501.47K | 431.63K | 431.63K | 102.32K | 102.32K | 52.08K | 52.08K | 31.10K | 31.10K | 28.78K | 28.78K | 28.78K | 28.78K | 13.37K | 13.37K | 11.36K | 11.36K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $12.07M | $17.37M | $15.52M | $13.33M | $7.29M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $12.07M | $17.37M | $15.52M | $13.33M | $7.29M |
| Net Receivables | $1.35M | $1.34M | $4.91M | $7.77M | $10.65M |
| Inventory | $809.76K | $531.25K | $1.02M | $859.70K | $892.77K |
| Other Current Assets | $6.84K | $230.64K | $995.83K | $1.27M | $809.10K |
| Total Current Assets | $14.23M | $19.52M | $22.45M | $23.23M | $19.64M |
| Property Plant Equipment Net | $564.69K | $1.27M | $1.59M | $1.79M | $1.90M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $19.10K | $27.87K | $38.76K | $45.80K | $50.05K |
| Goodwill and Intangible Assets | $19.10K | $27.87K | $38.76K | $45.80K | $50.05K |
| Long Term Investments | $- | $- | $- | $- | $-441.21K |
| Tax Assets | $- | $- | $- | $321.44K | $112.84K |
| Other Non-Current Assets | $8.31M | $8.74M | $9.46M | $9.16M | $441.21K |
| Total Non-Current Assets | $8.89M | $10.03M | $11.09M | $11.31M | $2.07M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $23.13M | $29.55M | $33.55M | $34.55M | $21.70M |
| Account Payables | $1.28M | $1.38M | $1.48M | $1.46M | $1.94M |
| Short Term Debt | $2.35M | $3.39M | $2.05M | $37.12K | $6.69M |
| Tax Payables | $1.05M | $1.10M | $1.17M | $1.16M | $986.84K |
| Deferred Revenue | $187.66K | $165.53K | $77.37K | $257.45K | $298.04K |
| Other Current Liabilities | $4.03M | $8.46M | $12.35M | $15.67M | $2.35M |
| Total Current Liabilities | $8.90M | $14.50M | $17.12M | $18.58M | $12.26M |
| Long Term Debt | $294.67K | $365.82K | $- | $6.29K | $36.51K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $294.67K | $365.82K | $3.61M | $6.29K | $36.51K |
| Other Liabilities | $- | $- | $-3.61M | $- | $- |
| Total Liabilities | $9.20M | $14.86M | $17.12M | $18.59M | $12.30M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $4.35M | $913.78K | $162.47K | $62.06K | $34.67K |
| Retained Earnings | $-24.71M | $-21.61M | $-15.69M | $-9.95M | $-7.20M |
| Accumulated Other Comprehensive Income Loss | $-1.03M | $-197.57K | $956.14K | $527.79K | $-590.66K |
| Other Total Stockholders Equity | $35.32M | $35.59M | $30.99M | $25.32M | $17.16M |
| Total Stockholders Equity | $13.93M | $14.69M | $16.42M | $15.96M | $9.40M |
| Total Equity | $13.93M | $14.69M | $16.42M | $15.96M | $9.40M |
| Total Liabilities and Stockholders Equity | $23.13M | $29.55M | $33.55M | $34.55M | $21.70M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $23.13M | $29.55M | $33.55M | $34.55M | $21.70M |
| Total Investments | $-6.84K | $- | $- | $- | $-441.21K |
| Total Debt | $2.65M | $3.76M | $2.05M | $43.41K | $6.72M |
| Net Debt | $-9.42M | $-13.61M | $-13.48M | $-13.29M | $-563.16K |
Balance Sheet Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $12.07M | $12.07M | $11.47M | $11.47M | $17.37M | $17.37M | $2.98M | $2.98M | $15.52M | $15.52M | $31.32K | $31.32K | $13.33M | $13.33M | $10.35M | $10.35M | $7.29M | $7.29M | $8.25M | $8.25M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $12.07M | $12.07M | $11.47M | $11.47M | $17.37M | $17.37M | $2.98M | $2.98M | $15.52M | $15.52M | $31.32K | $31.32K | $13.33M | $13.33M | $10.35M | $10.35M | $7.29M | $7.29M | $8.25M | $8.25M |
| Net Receivables | $1.35M | $1.31M | $1.31M | $1.31M | $1.58M | $1.34M | $3.32M | $3.32M | $3.37M | $3.37M | $10.06M | $3.88M | $7.77M | $4.51M | $9.53M | $5.58M | $10.65M | $3.84M | $7.90M | $4.57M |
| Inventory | $794.86K | $809.76K | $581.32K | $581.32K | $531.25K | $577.56K | $628.19K | $686.31K | $1.02M | $1.07M | $837.45K | $1.37M | $859.70K | $1.38M | $867.28K | $1.35M | $892.77K | $1.05M | $846.28K | $1.13M |
| Other Current Assets | $53.38K | $38.48K | $137.98K | $137.98K | $- | $230.64K | $641.28K | $5.37M | $2.54M | $2.49M | $6.91M | $6.38M | $1.27M | $4.01M | $5.26M | $4.78M | $809.10K | $7.47M | $3.88M | $3.60M |
| Total Current Assets | $14.23M | $14.23M | $13.50M | $13.50M | $19.52M | $19.52M | $12.36M | $12.36M | $22.45M | $22.45M | $11.66M | $11.66M | $23.23M | $23.23M | $22.06M | $22.06M | $19.64M | $19.64M | $17.54M | $17.54M |
| Property Plant Equipment Net | $564.69K | $564.69K | $1.07M | $1.07M | $1.27M | $1.27M | $1.36M | $1.36M | $1.59M | $1.59M | $1.65M | $1.65M | $1.79M | $1.79M | $1.91M | $1.91M | $1.90M | $1.90M | $1.94M | $1.94M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $19.10K | $19.10K | $22.51K | $22.51K | $27.87K | $27.87K | $30.72K | $30.72K | $38.76K | $38.76K | $42.35K | $42.35K | $45.80K | $45.80K | $48.20K | $48.20K | $50.05K | $50.05K | $53.39K | $53.39K |
| Goodwill and Intangible Assets | $19.10K | $19.10K | $22.51K | $22.51K | $27.87K | $27.87K | $30.72K | $30.72K | $38.76K | $38.76K | $42.35K | $42.35K | $45.80K | $45.80K | $48.20K | $48.20K | $50.05K | $50.05K | $53.39K | $53.39K |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-530.37K | $- | $-112.85K | $- | $3.50M | $3.50M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $321.44K | $- | $23.37K | $- | $112.84K | $- | $12.68K | $- |
| Other Non-Current Assets | $8.31M | $8.31M | $-1 | $- | $8.74M | $8.74M | $8.43M | $8.43M | $9.46M | $9.46M | $9.31M | $9.31M | $9.16M | $9.48M | $530.37K | $23.37K | $112.85K | $112.84K | $- | $12.68K |
| Total Non-Current Assets | $8.89M | $8.89M | $1.09M | $1.09M | $10.03M | $10.03M | $9.82M | $9.82M | $11.09M | $11.09M | $11.01M | $11.01M | $11.31M | $11.31M | $1.98M | $1.98M | $2.07M | $2.07M | $5.50M | $5.50M |
| Other Assets | $-1 | $- | $1 | $- | $- | $- | $2 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $23.13M | $23.13M | $14.59M | $14.59M | $29.55M | $29.55M | $22.18M | $22.18M | $33.55M | $33.55M | $22.67M | $22.67M | $34.55M | $34.55M | $24.04M | $24.04M | $21.70M | $21.70M | $23.05M | $23.05M |
| Account Payables | $1.28M | $1.28M | $1.32M | $1.32M | $1.38M | $1.38M | $1.56M | $1.56M | $1.48M | $1.48M | $1.49M | $1.49M | $1.46M | $1.46M | $1.36M | $1.36M | $1.94M | $1.94M | $1.96M | $1.96M |
| Short Term Debt | $2.35M | $3.40M | $2.84M | $3.26M | $3.39M | $8.59M | $1.21M | $1.58M | $2.05M | $10.74M | $24.04K | $2.63M | $37.12K | $12.19M | $45.76K | $580.09K | $6.69M | $6.69M | $5.04M | $6.88M |
| Tax Payables | $1.05M | $- | $1.04M | $- | $1.10M | $- | $1.07M | $- | $1.17M | $- | $1.18M | $- | $1.16M | $- | $1.32M | $- | $986.84K | $- | $1.03M | $- |
| Deferred Revenue | $1.05M | $1.65M | $190.19K | $- | $165.53K | $- | $65.10K | $- | $77.37K | $- | $218.64K | $- | $257.45K | $- | $217.41K | $- | $298.04K | $- | $120.58K | $- |
| Other Current Liabilities | $3.17M | $4.22M | $4.01M | $4.62M | $8.62M | $4.52M | $3.45M | $4.16M | $12.35M | $4.90M | $6.18M | $4.76M | $15.67M | $4.94M | $2.78M | $3.57M | $2.35M | $3.64M | $2.73M | $1.93M |
| Total Current Liabilities | $8.90M | $8.90M | $9.20M | $9.20M | $14.50M | $14.50M | $7.29M | $7.29M | $17.12M | $17.12M | $8.88M | $8.88M | $18.58M | $18.58M | $5.51M | $5.51M | $12.26M | $12.26M | $10.76M | $10.76M |
| Long Term Debt | $294.67K | $294.67K | $311.51K | $311.51K | $365.82K | $365.82K | $- | $- | $- | $- | $- | $- | $6.29K | $6.29K | $15.21K | $15.21K | $36.51K | $36.51K | $873.28K | $873.28K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $294.67K | $294.67K | $311.51K | $311.51K | $365.82K | $365.82K | $2.83M | $- | $3.61M | $- | $- | $- | $6.29K | $6.29K | $15.21K | $15.21K | $36.51K | $36.51K | $873.28K | $873.28K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $-2.83M | $- | $-3.61M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $9.20M | $9.20M | $9.51M | $9.51M | $14.86M | $14.86M | $7.29M | $7.29M | $17.12M | $17.12M | $8.88M | $8.88M | $18.59M | $18.59M | $5.52M | $5.52M | $12.30M | $12.30M | $11.64M | $11.64M |
| Preferred Stock | $- | $35.32M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3 | $- | $- | $- |
| Common Stock | $4.35M | $4.35M | $1.45M | $1.45M | $913.78K | $913.78K | $288.08K | $288.08K | $162.47K | $162.47K | $67.44K | $67.44K | $62.06K | $62.06K | $62.06K | $62.06K | $34.67K | $34.67K | $23.22K | $23.22K |
| Retained Earnings | $-24.71M | $-24.71M | $-31.31M | $-31.31M | $-21.61M | $-21.61M | $-17.18M | $-17.18M | $-15.69M | $-15.69M | $-13.04M | $-13.04M | $-9.95M | $-9.95M | $-5.82M | $-5.82M | $-7.20M | $-7.20M | $735.80K | $735.80K |
| Accumulated Other Comprehensive Income Loss | $-1.03M | $-1.03M | $-1.02M | $-1.02M | $-197.57K | $-197.57K | $-779.39K | $-779.39K | $956.14K | $956.14K | $758.82K | $758.82K | $527.79K | $527.78K | $48.12K | $48.12K | $-590.66K | $-590.66K | $-756.92K | $-756.92K |
| Other Total Stockholders Equity | $35.32M | $35.32M | $35.95M | $35.95M | $35.59M | $35.59M | $32.56M | $32.56M | $30.99M | $30.99M | $26.01M | $26.01M | $25.32M | $25.32M | $24.23M | $24.23M | $17.16M | $17.16M | $11.41M | $11.41M |
| Total Stockholders Equity | $13.93M | $13.93M | $5.08M | $5.08M | $14.69M | $14.69M | $14.89M | $14.89M | $16.42M | $16.42M | $13.79M | $13.79M | $15.96M | $15.96M | $18.52M | $18.52M | $9.40M | $9.40M | $11.41M | $11.41M |
| Total Equity | $13.93M | $13.93M | $5.08M | $5.08M | $14.69M | $14.69M | $14.89M | $14.89M | $16.42M | $16.42M | $13.79M | $13.79M | $15.96M | $15.96M | $18.52M | $18.52M | $9.40M | $9.40M | $11.41M | $11.41M |
| Total Liabilities and Stockholders Equity | $23.13M | $23.13M | $14.59M | $14.59M | $29.55M | $29.55M | $22.18M | $22.18M | $33.55M | $33.55M | $22.67M | $22.67M | $34.55M | $34.55M | $24.04M | $24.04M | $21.70M | $21.70M | $23.05M | $23.05M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $23.13M | $23.13M | $14.59M | $14.59M | $29.55M | $29.55M | $22.18M | $22.18M | $33.55M | $33.55M | $22.67M | $22.67M | $34.55M | $34.55M | $24.04M | $24.04M | $21.70M | $21.70M | $23.05M | $23.05M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-530.37K | $- | $-112.85K | $- | $3.50M | $3.50M |
| Total Debt | $2.65M | $3.46M | $3.15M | $3.52M | $3.76M | $8.90M | $1.21M | $1.21M | $2.05M | $10.74M | $24.04K | $2.14M | $43.41K | $12.19M | $60.97K | $60.97K | $6.72M | $6.72M | $5.92M | $7.75M |
| Net Debt | $-9.42M | $-8.61M | $-8.31M | $-7.95M | $-13.61M | $-8.47M | $-1.77M | $-1.77M | $-13.48M | $-4.78M | $-7.28K | $2.11M | $-13.29M | $-1.14M | $-10.29M | $-10.29M | $-563.16K | $-563.16K | $-2.33M | $-496.69K |
Annual Cash Flow
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-3.10M | $-5.93M | $-5.74M | $-2.75M | $-10.29M |
| Depreciation and Amortization | $203.25K | $250.16K | $320.01K | $345.41K | $331.84K |
| Deferred Income Tax | $- | $3.23M | $328.15K | $-192.68K | $-101.72K |
| Stock Based Compensation | $352.10K | $554.57K | $2.33M | $- | $- |
| Change in Working Capital | $-381.56K | $1.42M | $1.90M | $-1.61M | $1.95M |
| Accounts Receivables | $-321.42K | $912.95K | $831.47K | $-519.24K | $104.00K |
| Inventory | $-190.29K | $408.95K | $-180.80K | $38.62K | $39.71K |
| Accounts Payables | $-29.25K | $9.70K | $-22.79K | $-619.54K | $302.27K |
| Other Working Capital | $159.41K | $83.91K | $1.28M | $-506.08K | $1.50M |
| Other Non Cash Items | $996.69K | $408.69K | $1.12M | $1.62M | $3.35M |
| Net Cash Provided by Operating Activities | $-1.93M | $-80.76K | $268.29K | $-1.32M | $934.25K |
| Investments in Property Plant and Equipment | $-7.06K | $-70.68K | $-62.49K | $-93.04K | $-406.66K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $-8.85M | $-3.59M |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $33.49K | $58.38K | $15.58K | $3.13M | $-1.50M |
| Net Cash Used for Investing Activities | $26.42K | $-12.30K | $-46.91K | $-5.81M | $-5.50M |
| Debt Repayment | $1.31M | $4.00M | $2.77M | $-124.95K | $8.80M |
| Common Stock Issued | $- | $2.19M | $3.12M | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-3.93M | $-3.26M | $-4.29M | $12.53M | $-5.78M |
| Net Cash Used Provided by Financing Activities | $-2.62M | $2.94M | $1.60M | $12.41M | $3.02M |
| Effect of Forex Changes on Cash | $-765.23K | $-1.05M | $394.12K | $784.54K | $-466.81K |
| Net Change in Cash | $-5.29M | $1.80M | $2.21M | $6.07M | $-2.00M |
| Cash at End of Period | $12.08M | $17.37M | $15.57M | $13.36M | $7.29M |
| Cash at Beginning of Period | $17.37M | $15.57M | $13.36M | $7.29M | $9.29M |
| Operating Cash Flow | $-1.93M | $-80.76K | $268.29K | $-1.32M | $934.25K |
| Capital Expenditure | $-7.06K | $-70.68K | $-62.49K | $-93.04K | $-406.66K |
| Free Cash Flow | $-1.94M | $-151.44K | $205.80K | $-1.41M | $527.59K |
Cash Flow Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $3.30M | $3.30M | $-4.85M | $-4.85M | $-2.22M | $-2.22M | $-747.30K | $-747.30K | $-2.64M | $-1.32M | $-3.09M | $-1.55M | $-4.13M | $-2.06M | $1.38M | $690.63K | $-7.94M | $-3.97M | $-2.35M | $-1.17M |
| Depreciation and Amortization | $90.28K | $90.28K | $157.73K | $51.38K | $70.10K | $70.10K | $54.98K | $54.98K | $134.01K | $67.00K | $186.00K | $93.00K | $162.49K | $81.24K | $182.93K | $91.46K | $198.30K | $99.15K | $133.54K | $66.77K |
| Deferred Income Tax | $- | $- | $- | $- | $750.50K | $-845.84K | $-163.52K | $- | $2.37K | $- | $325.78K | $- | $-284.17K | $- | $91.48K | $- | $-101.72K | $- | $- | $- |
| Stock Based Compensation | $176.05K | $176.05K | $- | $- | $138.64K | $138.64K | $138.64K | $138.64K | $1.00M | $1.00M | $162.89K | $162.89K | $- | $- | $- | $- | $- | $- | $- | $- |
| Change in Working Capital | $-325.96K | $-325.96K | $149.03K | $149.03K | $709.48K | $709.48K | $-20.10K | $-20.10K | $-909.55K | $-419.50K | $2.81M | $1.40M | $825.16K | $495.47K | $-2.43M | $-1.03M | $3.49M | $1.75M | $-1.32M | $-919.12K |
| Accounts Receivables | $-124.23K | $-124.23K | $-36.48K | $-36.48K | $642.84K | $642.84K | $-186.37K | $-186.37K | $98.59K | $66.83K | $697.80K | $348.90K | $1.03M | $514.58K | $-1.53M | $-774.20K | $749.77K | $384.17K | $-585.50K | $-332.17K |
| Inventory | $-75.87K | $-75.87K | $-19.28K | $-19.28K | $64.36K | $64.36K | $140.19K | $140.19K | $268.88K | $134.44K | $31.24K | $15.62K | $-51.78K | $-25.89K | $-250.74K | $-125.37K | $68.50K | $34.25K | $125.86K | $62.93K |
| Accounts Payables | $- | $- | $19.35K | $- | $-244.28K | $- | $253.97K | $- | $-34.38K | $- | $11.59K | $- | $26.32K | $- | $-645.85K | $- | $-87.25K | $- | $389.51K | $- |
| Other Working Capital | $-125.87K | $-125.87K | $204.79K | $204.79K | $2.28K | $2.28K | $26.08K | $26.08K | $-1.24M | $-620.78K | $2.07M | $1.03M | $-179.09K | $6.78K | $-4.36K | $-134.96K | $2.76M | $1.33M | $-1.25M | $-649.87K |
| Other Non Cash Items | $-3.91M | $-3.91M | $4.25M | $4.36M | $1.54M | $1.54M | $299.22K | $299.22K | $3.93M | $960.65K | $-913.55K | $-264.58K | $1.76M | $996.48K | $3.24M | $85.69K | $7.04M | $3.60M | $2.01M | $1.01M |
| Net Cash Provided by Operating Activities | $-674.24K | $-674.24K | $-289.78K | $-289.78K | $234.18K | $234.18K | $-274.56K | $-274.56K | $580.64K | $290.32K | $-312.35K | $-156.18K | $-983.05K | $-491.53K | $-333.51K | $-166.75K | $3.02M | $1.48M | $-1.86M | $-1.01M |
| Investments in Property Plant and Equipment | $-3.53K | $-3.53K | $- | $- | $-25.28K | $-25.28K | $-10.06K | $-10.06K | $-41.35K | $-20.68K | $-21.14K | $-10.57K | $26.17K | $13.09K | $-119.22K | $-59.61K | $-32.94K | $-16.47K | $-373.72K | $-186.86K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-8.85M | $- | $- | $- | $-1.48M | $- | $-3.61M | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2.86M | $- | $2.86M | $- | $- | $- | $- | $- |
| Other Investing Activities | $6.92K | $6.92K | $9.82K | $9.82K | $-523 | $-523 | $29.71K | $29.71K | $9.30M | $4.65M | $-9.28M | $-4.64M | $3.13M | $-4.28M | $1.43M | $1.43M | $1.50M | $12.05K | $-1.50M | $-2.56M |
| Net Cash Used for Investing Activities | $3.39K | $3.39K | $9.82K | $9.82K | $-25.81K | $-25.81K | $19.66K | $19.66K | $9.26M | $4.63M | $-9.30M | $-4.65M | $-8.54M | $-4.27M | $2.74M | $1.37M | $-8.84K | $-4.42K | $-5.49M | $-2.74M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $2.19M | $- | $- | $- | $3.12M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $918.65K | $918.65K | $-2.23M | $-2.23M | $7.01M | $7.01M | $-5.53M | $-5.53M | $5.50M | $2.75M | $-3.91M | $-1.95M | $12.13M | $6.07M | $274.50K | $137.25K | $-3.95M | $-1.94M | $3.46M | $3.46M |
| Net Cash Used Provided by Financing Activities | $918.65K | $918.65K | $-2.23M | $-2.23M | $7.01M | $7.01M | $-5.53M | $-5.53M | $5.50M | $2.75M | $-3.91M | $-1.95M | $12.13M | $6.07M | $274.50K | $137.25K | $-3.95M | $-1.94M | $6.75M | $3.46M |
| Effect of Forex Changes on Cash | $58.28K | $58.28K | $-440.90K | $-440.90K | $-20.14K | $-20.14K | $-504.71K | $-504.71K | $98.76K | $98.76K | $98.30K | $98.30K | $198.57K | $198.56K | $193.70K | $193.70K | $-48.63K | $-48.63K | $-184.78K | $-184.78K |
| Net Change in Cash | $306.08K | $306.08K | $-5.90M | $-2.95M | $14.39M | $4.21M | $-12.59M | $-6.29M | $15.54M | $7.77M | $-13.33M | $-6.66M | $3.01M | $1.50M | $3.07M | $1.53M | $-960.04K | $-518.60K | $-782.92K | $-483.85K |
| Cash at End of Period | $306.08K | $306.08K | $11.47M | $-2.95M | $17.37M | $7.19M | $2.98M | $-6.29M | $15.57M | $7.80M | $31.32K | $6.70M | $13.36M | $11.86M | $10.35M | $8.82M | $7.29M | $7.81M | $8.32M | $-483.85K |
| Cash at Beginning of Period | $- | $- | $17.37M | $- | $2.98M | $2.98M | $15.57M | $- | $31.32K | $31.32K | $13.36M | $13.36M | $10.35M | $10.35M | $7.29M | $7.29M | $8.25M | $8.32M | $9.11M | $- |
| Operating Cash Flow | $-674.24K | $-674.24K | $-289.78K | $-289.78K | $234.18K | $234.18K | $-274.56K | $-274.56K | $580.64K | $290.32K | $-312.35K | $-156.18K | $-983.05K | $-491.53K | $-333.51K | $-166.75K | $3.02M | $1.48M | $-1.86M | $-1.01M |
| Capital Expenditure | $-3.53K | $-3.53K | $- | $- | $-25.28K | $-25.28K | $-10.06K | $-10.06K | $-41.35K | $-20.68K | $-21.14K | $-10.57K | $26.17K | $13.09K | $-119.22K | $-59.61K | $-32.94K | $-16.47K | $-373.72K | $-186.86K |
| Free Cash Flow | $-677.77K | $-677.77K | $-289.78K | $-289.78K | $208.90K | $208.90K | $-284.62K | $-284.62K | $539.29K | $269.65K | $-333.49K | $-166.74K | $-956.88K | $-478.44K | $-452.73K | $-226.36K | $2.99M | $1.46M | $-2.24M | $-1.20M |
China SXT Pharmaceuticals Dividends
Explore China SXT Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
China SXT Pharmaceuticals News
Read the latest news about China SXT Pharmaceuticals, including recent articles, headlines, and updates.
China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency
TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) (the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that the Company received a written notification (the “Compliance Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”) and the matter is closed.
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
TAIZHOU, China, Feb. 21, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective on February 25, 2025 (the “Share Consolidation”). The Company's ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on February 25, 2025. Upon the market opening on February 25, 2025, the Company's ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol “SXTC” with the new CUSIP number G2161P157.
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
Jiangsu, China, , Oct. 07, 2024 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (“SXTC” or the “Company”), (NASDAQ: SXTC) announced today that on October 3, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2).
China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule
TAIZHOU, China, Oct. 26, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that on October 19, 2023, NASDAQ notified us that it has determined that for the 10 consecutive business days, from October 5, 2023 to October 13, 2023, the closing bid price of the Company's ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter.
Is China SXT Pharmaceuticals, Inc. (SXTC) A Good Stock To Buy?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of capital and have to conduct due diligence while choosing their next pick. They don't always get it right, but, on average, their stock picks historically generated strong returns after adjusting for known risk factors. With this in mind, let's take a look at the recent hedge fund activity surrounding China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC).
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for SXTC.